Advertisement

A recombinant multi-epitope peptide vaccine based on MOMP and CPSIT_p6 protein protects against Chlamydia psittaci lung infection

  • Yumeng Li
  • Kang Zheng
  • Yuan Tan
  • Yating Wen
  • Chuan Wang
  • Qian Chen
  • Jian Yu
  • Man Xu
  • Manyi Tan
  • Yimou WuEmail author
Applied microbial and cell physiology
  • 74 Downloads

Abstract

Chlamydia psittaci is an obligate intracellular pathogen with a broad host range that can lead to severe infectious disease by transferring from birds to humans. Vaccination has been considered the best way to prevent chlamydial infection; nevertheless, there is currently still no commercially available vaccine that can inhibit the spread of C. psittaci. In previous study, major outer membrane protein (MOMP) of C. psittaci was confirmed to be an appropriate candidate antigen for limiting C. psittaci respiratory infections in a murine model, and plasmid-encoded CPSIT_p6 also has functions similar to those of MOMP in our study. Therefore, according to bioinformatics analysis, we developed a recombinant peptide containing multiple antigenic epitopes from MOMP (24–32, 262–272) and CPSIT_p6 protein (109–119, 173–181) and evaluated the efficacy of peptide immunization. BALB/c mice were inoculated intraperitoneally with the recombinant multi-epitope antigens three times at 2-week intervals and subsequently intranasally infected with C. psittaci. We found that the recombinant multi-epitope antigens induced strong humoral and Th1 cellular immune responses by producing meaningfully high levels of antigen-specific antibodies, interferon-gamma (IFN-γ), or interleukin-2 (IL-2). Vaccination significantly reduced the bacterial burden and the degree of inflammation in the infected lungs and led to lower levels of IFN-γ and IL-6. Furthermore, adoptive transfer of CD4+ splenocytes harvested from the vaccinated mice produced a significantly lower chlamydial load, indicating the importance of the cellular immune response. Therefore, the recombinant multi-epitope antigens may provide the basis for a new peptide-based vaccine against C. psittaci infection.

Keywords

Chlamydia psittaci Epitope Vaccine Major outer membrane protein Chlamydial infection 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 81671986, Grant No. 31600150), the Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control Foundation (Grant No. 2014-5), the Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study (Grant No. 2015-351), and the Foundation of the First Hospital of Changsha City (Grant No. Y2018-18).

Compliance with ethical standards

Ethical statement

All animal procedures and treatments were approved by the Animal Welfare and Ethics Committee of the University of South China and were performed in accordance with the regulations of the institution.

Conflicts of interest

The authors declare that they have no conflicts of interest

Supplementary material

253_2018_9513_MOESM1_ESM.pdf (268 kb)
ESM 1 (PDF 268 kb)

References

  1. Choubini E, Habibi M, Khorshidi A, Ghasemi A, Asadi Karam MR, Bouzari S (2018) A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model. Mol Immunol 96:88–97CrossRefGoogle Scholar
  2. Coler RN, Bhatia A, Maisonneuve JF, Probst P, Barth B, Ovendale P, Fang H, Alderson M, Lobet Y, Cohen J, Mettens P, Reed SG (2009) Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol 55:258–270CrossRefGoogle Scholar
  3. Cunningham KA, Carey AJ, Hafner L, Timms P, Beagley KW (2011) Chlamydia muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo. Am J Reprod Immunol 65:118–126CrossRefGoogle Scholar
  4. Dixit S, Singh SR, Yilma AN, Agee RD 2nd, Taha M, Dennis VA (2014) Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. Nanomedicine 10:1311–1321CrossRefGoogle Scholar
  5. Dutow P, Fehlhaber B, Bode J, Laudeley R, Rheinheimer C, Glage S, Wetsel RA, Pabst O, Klos A (2014) The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response. J Infect Dis 209:1269–1278CrossRefGoogle Scholar
  6. Eko FO, He Q, Brown T, McMillan L, Ifere GO, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Igietseme JU (2004) A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 173:3375–3382CrossRefGoogle Scholar
  7. Engler OB, Dai WJ, Sette A, Hunziker IP, Reichen J, Pichler WJ, Cerny A (2001) Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol Immunol 38:457–465CrossRefGoogle Scholar
  8. Fairley SJ, Singh SR, Yilma AN, Waffo AB, Subbarayan P, Dixit S, Taha MA, Cambridge CD, Dennis VA (2013) Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomedicine 8:2085–2099PubMedPubMedCentralGoogle Scholar
  9. Ferrante A (2013) For many but not for all: how the conformational flexibility of the peptide/MHCII complex shapes epitope selection. Immunol Res 56:85–95CrossRefGoogle Scholar
  10. Hu Y, Chen L, Wang C, Xie Y, Chen Z, Liu L, Su Z, Wu Y (2015) Transcriptional analysis of 10 selected genes in a model of penicillin G induced persistence of Chlamydophila psittaci in HeLa cells. J Microbiol Biotechnol 25:1246–1256CrossRefGoogle Scholar
  11. Jiang P, Cai Y, Chen J, Ye X, Mao S, Zhu S, Xue X, Chen S, Zhang L (2017) Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model. Vaccine 35:3096–3103CrossRefGoogle Scholar
  12. Liang M, Wen Y, Ran O, Chen L, Wang C, Li L, Xie Y, Zhang Y, Chen C, Wu Y (2016) Protective immunity induced by recombinant protein CPSIT_p8 of Chlamydia psittaci. Appl Microbiol Biotechnol 100:6385–6393CrossRefGoogle Scholar
  13. Liang S, Bulir D, Kaushic C, Mahony J (2017) Considerations for the rational design of a Chlamydia vaccine. Hum Vaccin Immunother 13:831–835CrossRefGoogle Scholar
  14. Longbottom D, Livingstone M (2006) Vaccination against chlamydial infections of man and animals. Vet J 171:263–275CrossRefGoogle Scholar
  15. Marks E, Verolin M, Stensson A, Lycke N (2007) Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection. Infect Immun 75:4638–4647CrossRefGoogle Scholar
  16. Mosolygo T, Szabo AM, Balogh EP, Faludi I, Virok DP, Endresz V, Samu A, Krenacs T, Burian K (2014) Protection promoted by pGP3 or pGP4 against Chlamydia muridarum is mediated by CD4(+) cells in C57BL/6N mice. Vaccine 32:5228–5233CrossRefGoogle Scholar
  17. O'Meara CP, Armitage CW, Harvie MC, Timms P, Lycke NY, Beagley KW (2013) Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology. PLoS One 8:e61962CrossRefGoogle Scholar
  18. Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R (2018) Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci 109:550–559CrossRefGoogle Scholar
  19. Patterson R, Nerren J, Kogut M, Court P, Villarreal-Ramos B, Seyfert HM, Dalby P, Werling D (2012) Yeast-surface expressed BVDV E2 protein induces a Th1/Th2 response in naive T cells. Dev Comp Immunol 37:107–114CrossRefGoogle Scholar
  20. Ponomarenko J, Papangelopoulos N, Zajonc DM, Peters B, Sette A, Bourne PE (2011) IEDB-3D: structural data within the immune epitope database. Nucleic Acids Res 39(Database issue):D1164–D1170CrossRefGoogle Scholar
  21. Qiu C, Zhou J, Cao XA, Lin G, Zheng F, Gong X (2010) Immunization trials with an avian chlamydial MOMP gene recombinant adenovirus. Bioeng Bugs 1:267–273CrossRefGoogle Scholar
  22. Rockey DD, Wang J, Lei L, Zhong G (2009) Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines 8:1365–1377CrossRefGoogle Scholar
  23. Saadi M, Karkhah A, Nouri HR (2017) Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches. Infect Genet Evol 51:227–234CrossRefGoogle Scholar
  24. Saha S, Raghava GP (2007) Prediction methods for B-cell epitopes. Methods Mol Biol 409:387–394CrossRefGoogle Scholar
  25. Shewen PE, Povey RC, Wilson MR (1980) A comparison of the efficacy of a live and four inactivated vaccine preparations for the protection of cats against experimental challenge with Chlamydia psittaci. Can J Comp Med 44:244–251PubMedPubMedCentralGoogle Scholar
  26. Stagg AJ (1998) Vaccines against Chlamydia: approaches and progress. Mol Med Today 4:166–173CrossRefGoogle Scholar
  27. Su H, Caldwell HD (1995) CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 63:3302–3308PubMedPubMedCentralGoogle Scholar
  28. Szymanska-Czerwinska M, Niemczuk K (2016) Avian chlamydiosis zoonotic disease. Vector Borne Zoonotic Dis 16:1–3CrossRefGoogle Scholar
  29. Tahara M, Burckert JP, Kanou K, Maenaka K, Muller CP, Takeda M (2016) Measles virus hemagglutinin protein epitopes: the basis of antigenic stability. Viruses 8Google Scholar
  30. Tsuji M, Zavala F (2001) Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol Immunol 38:433–442CrossRefGoogle Scholar
  31. Tu J, Hou B, Wang B, Lin X, Gong W, Dong H, Zhu S, Chen S, Xue X, Zhao KN, Zhang L (2014) A multi-epitope vaccine based on Chlamydia trachomatis major outer membrane protein induces specific immunity in mice. Acta Biochim Biophys Sin 46:401–408CrossRefGoogle Scholar
  32. Vicetti Miguel RD, Cherpes TL (2012) Hypothesis: Chlamydia trachomatis infection of the female genital tract is controlled by type 2 immunity. Med Hypotheses 79:713–716CrossRefGoogle Scholar
  33. Voigt A, Schofl G, Saluz HP (2012) The Chlamydia psittaci genome: a comparative analysis of intracellular pathogens. PLoS One 7:e35097CrossRefGoogle Scholar
  34. Wang LF, Yu M (2004) Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. Curr Drug Targets 5:1–15CrossRefGoogle Scholar
  35. Wei X, Wang Y, Luo R, Qian W, Sizhu S, Zhou H (2017) Identification and characterization of a protective antigen, PlpB of bovine Pasteurella multocida strain LZ-PM. Dev Comp Immunol 71:1–7CrossRefGoogle Scholar
  36. Xu YF, Liu WL, Dong JQ, Liu WS, Feng QS, Chen LZ, Zeng YX, Zeng MS, Jia WH (2010) Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in cantonese. BMC Med Genet 11:161CrossRefGoogle Scholar
  37. Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham RC (2012) Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun 80:1510–1518CrossRefGoogle Scholar
  38. Zhang XX, Yu H, Wang XH, Li XZ, Zhu YP, Li HX, Luo SJ, Yuan ZG (2013) Protective efficacy against Chlamydophila psittaci by oral immunization based on transgenic rice expressing MOMP in mice. Vaccine 31:698–703CrossRefGoogle Scholar
  39. Zhihua L, Yuzhang W, Bo Z, Bing N, Li W (2004) Toward the quantitative prediction of T-cell epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A*0201. J Comput Biol 11:683–694CrossRefGoogle Scholar
  40. Zhong G (2017) Chlamydial plasmid-dependent pathogenicity. Trends Microbiol 25:141–152CrossRefGoogle Scholar
  41. Zhou J, Qiu C, Cao XA, Lin G (2007) Construction and immunogenicity of recombinant adenovirus expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci in chicks. Vaccine 25:6367–6372CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yumeng Li
    • 1
  • Kang Zheng
    • 1
  • Yuan Tan
    • 2
  • Yating Wen
    • 1
  • Chuan Wang
    • 1
  • Qian Chen
    • 1
  • Jian Yu
    • 3
  • Man Xu
    • 1
  • Manyi Tan
    • 1
  • Yimou Wu
    • 1
    Email author
  1. 1.Institution of Pathogenic Biology, Medical College, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hunan Province Cooperative Innovation Center for Molecular Target New Drug StudyUniversity of South ChinaHengyangChina
  2. 2.Department of DermatologyThe First Hospital of ChangshaChangshaChina
  3. 3.Department of Experimental Zoology, Medical CollegeUniversity of South ChinaHengyangChina

Personalised recommendations